Zobrazeno 1 - 10 of 56 pro vyhledávání: '"Erin P. Demakos"'
2
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
Autor: Shyamala C. Navada, Patrick S. Zbyszewski, Richard C. Woodman, Naveen Pemmaraju, Rosmy B. John, Guillermo Garcia-Manero, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, Steven M. Fruchtman, Maro Ohanian, Yesid Alvarado, Manoj Maniar
Publikováno v: Leukemia research. 94
Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes (MDS; n = 9), acute myeloid leukemia (AML; n = 8), and chronic myelomonocytic leukemia (CMML; n = 1) who were either hypomethylating agent naive (n = 10) or re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd5bd23ecb36503901cee3ce395699a
https://pubmed.ncbi.nlm.nih.gov/32442785
Zobrazit plný text záznamu
3
Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line
Autor: Shyamala C. Navada, Richa Rai, Stella M. Melana, Erin P. Demakos, Jonathan Feld, Foramben Patel, Lewis R. Silverman, Rosalie Odchimar-Reissig, E. Premkumar Reddy
Publikováno v: Blood. 138:4325-4325
Background: Myelodysplastic syndrome (MDS) is a clinically heterogenous disease of hematopoietic stem cells (HSC) characterized by ineffective hematopoiesis, uni/multi-lineage dysplasia and a high tendency to transform into acute myeloid leukemia. Ab
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31f9df62fd3c53004efddc99f5516a2e
https://doi.org/10.1182/blood-2021-152764
Zobrazit plný text záznamu
5
Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line
Autor: Foramben Patel, Shyamala C. Navada, Stella M. Melana, Rosalie Odchimar-Reissig, E. Premkumar Reddy, Erin P. Demakos, Jonathan Feld, Lewis R. Silverman, Richa Rai
Publikováno v: Blood. 136:35-36
Background Myelodysplastic Syndrome (MDS) is characterized by ineffective clonal hematopoiesis with peripheral blood cytopenias, leading to death from infection or bleeding. Azacitidine (AZA), a hypomethylating agent (HMA) is the standard of care for
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc654be7eccbf4e9b5d5080f81dc0d1b
https://doi.org/10.1182/blood-2020-142908
Zobrazit plný text záznamu
6
Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
Autor: Darshanie Sewah, Erin P. Demakos, Douglas Tremblay, Lewis R. Silverman, Shyamala C. Navada, Jonathan Feld, Rosalie Odchimar-Reissig, Saudia Alli
Publikováno v: Blood
Background: The COVID-19 (SARS-CoV-2) pandemic has affected cancer patients (pts) in a myriad of ways, including diagnostic & treatment delays, scarcity of blood products, and most importantly, higher risks of morbidity and mortality from the viral i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c676073558225ec5d9c3d798705c6601
https://doi.org/10.1182/blood-2020-138969
Zobrazit plný text záznamu
7
Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS)
Autor: Stella M. Melana, Richa Rai, Shyamala C. Navada, Rosalie Odchimar-Reissig, Erin P. Demakos, E. Premkumar Reddy, Lewis R. Silverman
Publikováno v: Cancer Research. 79:3026-3026
MDS is a heterogeneous stem cell disorder characterized by hyperproliferative bone marrow (BM) and peripheral blood cytopenias involving one or more lineages. AZA, a hypomethylating agent (HMA) is considered 1st line therapy for higher-risk disease.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::881190809239e68bbfb2d32c804186bd
https://doi.org/10.1158/1538-7445.am2019-3026
Zobrazit plný text záznamu
9
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
Autor: Rosalie Odchimar-Reissig, Erin P. Demakos, Shyamala C. Navada, Michael E. Petrone, Patrick S. Zbyszewski, Lewis R. Silverman, James F. Holland, Steven M. Fruchtman
Publikováno v: Leukemia research. 64
This Phase 1/2, dose-escalating study of rigosertib enrolled 22 patients with higher-risk myelodysplastic syndromes (MDS) (n=9) and acute myeloid leukemia (AML; n=13) who had relapsed or were refractory to standard therapy and for whom no second-line
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a5dfda58ccaedaedd71e1c3e55a994
https://pubmed.ncbi.nlm.nih.gov/29144985
Zobrazit plný text záznamu
10
The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome
Autor: Richa Rai, Shyamala C. Navada, Stella M. Melana, Rosalie Odchimar-Reissig, Erin P. Demakos, Lewis R. Silverman, E. Premkumar Reddy
Publikováno v: Blood. 134:4231-4231
Background: MDS is characterized by ineffective hematopoiesis and multiple cytopenias. Azacitidine (AZA), a hypomethylating agent (HMA), the standard therapy for higher-risk MDS patients (pts), improves hematopoiesis in 50% of MDS pts, with a median
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26c6971691f5fd39268d973aaed7ce82
https://doi.org/10.1182/blood-2019-130747
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje